Dnaprint Genomics Stock Cash And Equivalents
DNAPrint Genomics fundamentals help investors to digest information that contributes to DNAPrint Genomics' financial success or failures. It also enables traders to predict the movement of DNAPrint Stock. The fundamental analysis module provides a way to measure DNAPrint Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DNAPrint Genomics stock.
DNAPrint |
DNAPrint Genomics Company Cash And Equivalents Analysis
DNAPrint Genomics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current DNAPrint Genomics Cash And Equivalents | 134.35 K |
Most of DNAPrint Genomics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DNAPrint Genomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, DNAPrint Genomics has 134.35 K in Cash And Equivalents. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The cash and equivalents for all United States stocks is notably lower than that of the firm.
DNAPrint Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DNAPrint Genomics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DNAPrint Genomics could also be used in its relative valuation, which is a method of valuing DNAPrint Genomics by comparing valuation metrics of similar companies.DNAPrint Genomics is currently under evaluation in cash and equivalents category among its peers.
DNAPrint Fundamentals
| Return On Asset | -1.05 | |||
| Profit Margin | (2.36) % | |||
| Operating Margin | (7.31) % | |||
| Current Valuation | 5.21 M | |||
| Shares Outstanding | 644.61 M | |||
| Shares Owned By Institutions | 0.18 % | |||
| Price To Sales | 0.0003 X | |||
| Revenue | 2.43 M | |||
| Gross Profit | 754.07 K | |||
| EBITDA | (5.78 M) | |||
| Net Income | (12.35 M) | |||
| Cash And Equivalents | 134.35 K | |||
| Total Debt | 240 K | |||
| Current Ratio | 0.17 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (5.78 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 24 | |||
| Beta | 23.48 | |||
| Market Capitalization | 644 | |||
| Total Asset | 10.27 M | |||
| Retained Earnings | (45.53 M) | |||
| Working Capital | (9.35 M) | |||
| Current Asset | 1.89 M | |||
| Current Liabilities | 11.24 M | |||
| Net Asset | 10.27 M |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in DNAPrint Stock
If you are still planning to invest in DNAPrint Genomics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the DNAPrint Genomics' history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |